139 related articles for article (PubMed ID: 38454051)
21. Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
Claros OR; Tourinho-Barbosa RR; Fregeville A; Gallardo AC; Muttin F; Carneiro A; Stabile A; Moschini M; Macek P; Cathala N; Mombet A; Sanchez-Salas R; Cathelineau X
J Urol; 2020 May; 203(5):918-925. PubMed ID: 31821099
[TBL] [Abstract][Full Text] [Related]
22. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
23. Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
Hanske J; Risse Y; Roghmann F; Pucheril D; Berg S; Tully KH; von Landenberg N; Wald J; Noldus J; Brock M
Prostate; 2022 Feb; 82(2):227-234. PubMed ID: 34734428
[TBL] [Abstract][Full Text] [Related]
24. The urologist's learning curve of "in-bore" magnetic resonance-guided prostate biopsy.
Rosenzweig B; Drori T; Raz O; Goldinger G; Shlomai G; Zilberman DE; Shechtman M; Ramon J; Dotan ZA; Portnoy O
BMC Urol; 2021 Dec; 21(1):169. PubMed ID: 34872545
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?
Günzel K; Magheli A; Busch J; Baco E; Cash H; Heinrich S; Edler D; Schostak M; Borgmann H; Schlegel J; Hinz S
Int Urol Nephrol; 2022 Oct; 54(10):2477-2483. PubMed ID: 35877030
[TBL] [Abstract][Full Text] [Related]
26. A Prospective Comparison of Transrectal Standard, Cognitive, Transperineal Fusion, and Mapping Prostate Biopsy for Cancer Detection.
Petov V; Bazarkin A; Morozov A; Taratkin M; Ganzha T; Danilov S; Chernov Y; Chinenov D; Rzayev R; Suvorov A; Amosov A; Fajkovic H; Enikeev D; Krupinov G
J Endourol; 2023 Aug; 37(8):940-947. PubMed ID: 37294206
[No Abstract] [Full Text] [Related]
27. Stereotactic robot-assisted transperineal prostate biopsy under local anaesthesia and sedation: moving robotic biopsy from operating theatre to clinic.
Yang X; Lee AY; Law YM; Sim ASP; Tay KJ; Lau WKO; Ho HSS; Yuen JSP; Chen K
J Robot Surg; 2020 Oct; 14(5):767-772. PubMed ID: 32052276
[TBL] [Abstract][Full Text] [Related]
28. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
[TBL] [Abstract][Full Text] [Related]
30. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
[TBL] [Abstract][Full Text] [Related]
31. Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study.
Rakauskas A; Peters M; Martel P; van Rossum PSN; La Rosa S; Meuwly JY; Roth B; Valerio M
PLoS One; 2023; 18(1):e0280262. PubMed ID: 36652429
[TBL] [Abstract][Full Text] [Related]
32. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis.
Uleri A; Baboudjian M; Tedde A; Gallioli A; Long-Depaquit T; Palou J; Basile G; Gaya JM; Sanguedolce F; Lughezzani G; Rajwa P; Pradere B; Roupret M; Briganti A; Ploussard G; Breda A
Eur Urol Oncol; 2023 Dec; 6(6):621-628. PubMed ID: 37634971
[TBL] [Abstract][Full Text] [Related]
33. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
35. First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy.
Kaufmann S; Mischinger J; Amend B; Rausch S; Adam M; Scharpf M; Fend F; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Bedke J; Kruck S
World J Urol; 2017 Jul; 35(7):1023-1029. PubMed ID: 27847972
[TBL] [Abstract][Full Text] [Related]
36. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L
Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727
[TBL] [Abstract][Full Text] [Related]
37. The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy.
Maruf M; Fascelli M; George AK; Siddiqui MM; Kongnyuy M; DiBianco JM; Muthigi A; Valayil S; Sidana A; Frye TP; Kilchevsky A; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):179-185. PubMed ID: 28220802
[TBL] [Abstract][Full Text] [Related]
38. Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men.
Kongnyuy M; Siddiqui MM; George AK; Muthigi A; Sidana A; Maruf M; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):348-351. PubMed ID: 28440325
[TBL] [Abstract][Full Text] [Related]
39. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
40. Multiparametric MRI/TRUS Fusion Prostate Biopsy: Advantages of a Transperineal Approach.
Pepe P; Garufi A; Priolo GD; Pennisi M
Anticancer Res; 2017 Jun; 37(6):3291-3294. PubMed ID: 28551679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
